FDA Approved Indications for this Orphan Drug:

Treatment of adults (>18 years old) with metastatic renal cell carcinoma.

FDA Marketing Approval issued as of:
05/05/1992

Orphan Drug exclusivity ends on:
05/05/1999
Company Making and Marketing this drug:
Chiron Corporation

FDA Designation Date:
9/14/88

FDA Drug Designation:
Treatment of metastatic renal cell carcinoma.